The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Aspirin use and potential mechanisms for colorectal cancer prevention.
Open accessAbstract
Disease prevention is receiving more attention in the United States today. This welcome trend is largely a result of two economic forces: The increased level of support for prevention research by the National Institutes of Health (Healthy People 2000), and the potential payoff of prevention research in cutting the health care costs of managing patients with end-stage diseases. Indeed, the efficacy of preventive measures for many chronic diseases (such as heart disease and cancer) are being evaluated with the full expectation that mortality and morbidity—and perhaps health care costs—will decrease. One example of recent cancer prevention research indicates that there may be a 40–50% reduction in mortality from colorectal cancer in persons who take aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) 1 on a regular basis. It is clear that an effect of this magnitude would have a significant impact on both the number of lives saved and on the health care dollars recovered. Colorectal cancer is a major cause of death in Western civilizations, claiming about 55,000 lives in the United States this year alone. Americans have a 1 in 20 lifetime risk of developing this disease, and z 1 in 10 have a family member who develops colorectal cancer. Initially, it was hoped that early detection would reduce these high numbers. However, despite recent evidence that early detection by fecal occult blood tests and flexible sigmoidoscopy can decrease the risk of colorectal cancer death by 20–30%, most people do not undergo appropriate screening. Therefore, a number of laboratories have initiated research efforts focused on understanding the molecular basis of the potential chemoprotective effects resulting from aspirin and other NSAID use. It is hoped that this approach, in conjunction with more rigorous clinical trials, will lead to a rationale design for future colorectal cancer prevention regimens. This Perspectives article considers both the clinical and the basic research efforts underway this year, the 100th anniversary of the discovery of aspirin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310 · cited 5×
“These drugs were primarily developed as antiinflammatory agents that would lessen the gastrointestinal side effects caused by inhibition of COX-1.”
BackgroundInfluential
Cited by
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Self-citationCyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Self-citationHelicobacter pylori and gastrointestinal tract adenocarcinomas
Peek, R. M., & Blaser, M. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc703 · Cited by 1,813
Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
Wroblewski, L. E., Peek, R. M., & Wilson, K. T. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00011-10 · Cited by 1,442
Myofibroblasts. II. Intestinal subepithelial myofibroblasts
Powell, D. W., Mifflin, R. C., Valentich, J. D., Crowe, S. E., Saada, J. I., & West, A. B. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.2.c183 · Cited by 566
Metadata
- Authors
- Williams, C. S., Smalley, W., & DuBois, R. N.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-09-15
- Volume
- 100
- Issue
- 6
- Pages
- 1325-1329
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2090106927
- Cited by
- 244
- References
- 1
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.